eRx projected to reach $888M by 2019

The global market for e-prescribing will continue to grow, reaching $887.8 million in 2019, according to a report from Persistence Market Research.

The market, valued at $250.2 million in 2013, is expected to grow at a 23.5 percent annual compound rate from 2013 to 2019. The report reflects similar findings on the increasing uptake of e-prescribing recently noted by Surescripts, with a network that handled more transactions in 2014 than American Express (6 billion) and PayPal (4.2 billion).

In 2014, 56 percent of physicians and 95 percent of pharmacies processed 1.2 billion electronic prescriptions on the Surescripts network, the country's largest e-prescribing network, officials reported. That number includes 67 percent of all new prescriptions.

Improved healthcare infrastructure has increased the demand for e-prescribing systems, and the report says implementation of EHRs with e-prescribing systems "holds immense potential for the growth of e-prescribing market. However, the high cost of an e-prescribing system and lack of patient privacy and security impede growth of the market. Lack of high-speed broadband facilities and IT professionals in rural areas are also some of the key restraints," the researchers wrote.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.